Jing Ji Guan Cha Bao·2025-05-09 02:03Core Insights - BeiGene (ONC.O) reported a significant increase in total revenue for Q1 2025, reaching 8.048 billion yuan, a year-on-year growth of 50.2% [1] - The sales revenue from product sales was 7.985 billion yuan, reflecting a 49.9% increase compared to the previous year [1] Product Performance - The core product, Brukinsa (Zebutinib), achieved global sales of 5.692 billion yuan, marking a 63.7% increase year-on-year [1] - In the U.S. market, Brukinsa sales reached 4.041 billion yuan, up 61.9% year-on-year [1] - In Europe, sales amounted to 836 million yuan, a growth of 75.4% [1] - In China, sales were 590 million yuan, reflecting a 43.1% increase [1] - Another key product, Tislelizumab, generated sales of 1.245 billion yuan, with a year-on-year growth of 19.3% [1] - The growth of Tislelizumab was primarily driven by the inclusion of new indications in the medical insurance catalog in China and a significant increase in the number of hospitals carrying the drug [1] Financial Performance - BeiGene transitioned from a loss to profitability in Q1 2025, with adjusted operating profit of 1.171 billion yuan compared to an adjusted operating loss of 937 million yuan in the same period last year [1] - The adjusted net profit for the reporting period was 885 million yuan, a significant improvement from a net loss of 1.082 billion yuan in the previous year [1] Operational Efficiency - The overall performance improvement in Q1 2025 was attributed to substantial growth in product sales revenue and optimized expense management, which significantly enhanced the company's operational efficiency [2] - With the continued growth of core products and market expansion, BeiGene is expected to maintain a positive development trend in the future [2]